All go for Progen

JUNE 2010

EMBATTLED drug developer Progen Pharmaceuticals (PGL) has been granted a European patent for the preparation and use of its cancer therapeutic Muparfostat (PI-88).

Progen CEO Sue MacLeman says the patent grant will give the company greater coverage in a major pharmaceutical market.

Progen has also announced it plans to sublicence the technology to Taiwanese company Medigen Biotech Corp.

Amid board restructures and uncertainty for the biotech’s future, PGL shares have fallen by around 40 per cent in the last 12 months.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Four ways businesses can use artificial intelligence to triumph in 2022
Partner Content
The last two years have delivered major disruption to the technology industry and broad...
PROS
Advertisement

Related Stories

Brisbane Top Companies revealed

Brisbane Top Companies revealed

Brisbane’s top companies have been a hotbed of growth in 2021...

Brisbane Top Companies 1-10

Brisbane Top Companies 1-10

The top 10 Brisbane listed companies list has seldom changed as muc...

Brisbane Top Companies 11-20

Brisbane Top Companies 11-20

The 11-20 section of the Brisbane Top Companies list is founder-hea...

Brisbane Top Companies 21-30

Brisbane Top Companies 21-30

A battery tech spin-off and an initial public offering (IPO) have c...